Thalidomide and lenalidomide combine immunomodulatory and anti-angiogenic effects by inhibiting NF-κB activity, TNF-α expression, and (to a lesser extent) FGF-2 and VEGF expression in various tumor cell types [64,226]. The gene discussed is FGF2; the disease is neoplasm.